About the Company
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VRCA News
Verrica Pharma gains as FDA lists Ycanth in Orange Book
Verrica Pharmaceuticals (VRCA) receives FDA's NCE status for Ycanth, as FDA lists the antiviral in its Orange Book with five ...
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
NCE status provides a minimum of five years of regulatory exclusivityThe Company’s U.S. patents and pending patent applications related to ...
Verrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Facts
Verrica Pharmaceuticals Inc. (VRCA) announced the company's lead product, YCANTH, has received New Chemical Entity Status and a ...
Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript
Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Fourth Quarter and Year End 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is ...
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?
We feel now is a pretty good time to analyse Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA) business as it appears the company may be on the cusp of a considerable accomplishment. Verrica ...
Verrica Pharmaceuticals Inc VRCA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing ...
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
WEST CHESTER, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics ...
Verrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Facts
(RTTNews) - Verrica Pharmaceuticals Inc. (VRCA) announced the company's lead product, YCANTH, has received New Chemical Entity Status and a listing in the Orange Book from the FDA, providing a ...
Verrica Pharmaceuticals Inc VRCA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin ...
Verrica Pharmaceuticals Announces that YCANTH(TM) Receives New Chemical Entity Status and Orange Book Listing from the FDA
March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing ...
Loading the latest forecasts...